Ebrahim S. Delpassand, MD
Founder & Chairman of the Board/ CEO of RadioMedix (2006)
Dr. Ebrahim Delpassand is the founder, Chairman, and CEO of RadioMedix. In January of 2006, Dr. Delpassand Founded RadioMedix, a clinical stage biotechnology company with focus on development of new targeted radioactive diagnostic and therapeutic agents in the field of oncology. . He completed his residency training in Nuclear Medicine, and Anatomical and Clinical Pathology at Baylor College of Medicine in Houston in 1991. He is Board certified in Nuclear Medicine and Fellow of the American College of Nuclear Medicine. Dr. Delpassand is the former deputy chairman, associate professor, and chief of clinical nuclear medicine at M.D. Anderson Cancer Center in Houston, Texas. His credentials and extensive experience include the disciplines of therapeutic nuclear medicine, Peptide Receptor Radionuclide Therapy (PRRT), nuclear cardiology, monoclonal antibody imaging, and positron emission tomography (PET). Dr. Delpassand has been the principle investigator of multiple Investigational New Drug (IND) applications in the areas of diagnostic and Therapeutic Nuclear Medicine authorized by U.S. Food and Drug Administration (FDA), including the first Lu-177- DOTATATE PRRT , and first Lu-177 PSMA-617 INDs in the United States, among others. He holds an academic position as Clinical Professor in Radiation Oncology, at the University of Texas, Medical Branch
Dr. Delpassand has authored more than 90 peer reviewed manuscripts in the field of Nuclear Medicine, PRRT and Pathology and lectured in National and International meetings on PET, monoclonal antibody imaging, PRRT, and Therapeutic Nuclear Medicine.
Francisco Gras, MBA, MAC
Chief Financial Officer
Mr. Gras is a strategic senior financial executive with over 20 years of global experience. He leverages financial management to drive operational excellence and organizational growth, consistently achieving revenue and EBITDA targets for both emerging companies and major enterprises. Francisco has held leadership roles as CFO, VP of Finance, and Controller at organizations including Schlumberger, Atos, Geokinetics, and Axxis Geo Solutions. He earned a Master of Accounting from the University of North Carolina at Chapel Hill and an MBA from Baylor University.
Izabela Tworowska, Ph.D, MS.Pharm
Chief Scientific Officer & Co-Founder
Dr. Tworowska is a seasoned expert in clinical pharmacy, chemistry, and oncology research, with over 25 years of experience. She has led critical efforts in the CMC and preclinical evaluation of radiotheranostic drugs, supporting four successful IND submissions, and has served as Principal Investigator on five SBIR Phase I/II awards. A recognized leader in the field, Dr. Tworowska has received international honors including the IUPAC and Sigma-Aldrich Awards, and has co-authored more than 30 peer-reviewed publications. She is an active member of the NIH/NCI study section and currently leads the AlphaMedix project at RadioMedix.
Dr. Tworowska holds an M.S.Pharm (Clinical) from the Medical University, Poland and a Ph.D. in Chemistry from the Centre of Molecular and Macromolecular Studies at the Polish Academy of Sciences, with additional research experience at J.W. Goethe University in Frankfurt, Germany and William Rice Fellowship in Biochemistry at Rice University in Houston.
Ayda Delpassand, MSRS, MSGM
Director of Business Development and Project Management
Ms. Delpassand is an experienced regulatory affairs and clinical development professional with a strong background in advancing therapies through key stages of drug development. She provides strategic and regulatory support across IND and DMF submissions, guiding critical areas such as CMC, non-clinical, clinical operations, pharmacology and drug safety including data management, biostatistics, and medical writing. Her expertise in regulatory operations ensures that submissions consistently meet FDA standards, helping to drive successful drug development programs from early phase through commercialization.
Ms. Delpassand holds dual M.S. degrees in Regulatory Science and Global Medicine from the University of Southern California, Los Angeles, and a B.S. in Biology from San Diego State University.
Sergio Silva, MBA
Director of HR and Operations
Mr. Silva is a seasoned Human Resources leader with over 15 years of experience driving people strategy and organizational growth across healthcare, higher education, and tech environments. He specializes in talent development, employee engagement, and HR operations, with a strong track record of transforming workplace culture and reducing turnover. Passionate about aligning HR initiatives with business goals, Sergio brings a data-driven, people-first approach to every organization he supports.
He holds a Bachelor of Arts in Organizational Communication with a minor in Human Development from the University of Houston and a Master of Business Administration from Texas Woman’s University.
Azar Delpassand, RN, BSN
President & Co-Founder
Mrs. Delpassand is a seasoned healthcare entrepreneur with over 20 years of leadership in diagnostic imaging, nuclear medicine, and patient-centered care. She is the Founder and President of Excel Diagnostics & Nuclear Oncology Center, Co-Founder of RadioMedix, and past President & CEO of Infinity Infusion Care and Infinity Care, Inc., both recognized among the nation’s fastest-growing companies. As President of the RITA Foundation, Azar champions cancer awareness, education, and access to advanced therapies. Her career blends clinical expertise with a passion for innovation, driving initiatives that expand access to cutting-edge diagnostic and therapeutic solutions for patients worldwide.